Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Furosemide and Levodropropizine for Dyspnea
NCT06252454Phase 3Recruiting
- Sponsor
- Fakultní nemocnice Hradec Králové
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Dyspnea comparing Furosemide First with Placebo First (2 arms). Primary endpoint: Safety and tolerability of inhaled furosemide at 24 hours. Started Feb 2024; status: recruiting.
02
Drugs
furosemide
03
Conditions
Dyspnea
Beyond the preview
Go deeper on NCT06252454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252454.